S&P 500
7,511.60
+0.28%
Dow Jones
52,417.60
+0.12%
Nasdaq 100
30,003.80
+0.46%
Russell 2000
3,018.56
+0.18%
FTSE 100
10,509.10
+0.20%
Nikkei 225
69,792.30
+0.23%
Charles River Laboratories

Charles River Laboratories (CRL) Q3 2025 Earnings

Reported Nov 5, 2025 at 7:16 AM ET · SEC Source

Q3 25 EPS

$2.43

BEAT +3.86%

Est. $2.34

Q3 25 Revenue

$1.00B

BEAT +1.42%

Est. $990.8M

vs S&P Since Q3 25

+28.2%

BEATING MARKET

CRL +39.4% vs S&P +11.3%

Market Reaction

Did CRL Beat Earnings? Q3 2025 Results

Charles River Laboratories posted a modest but meaningful beat in its third-quarter 2025 results, with non-GAAP EPS of $2.43 clearing the $2.34 consensus estimate by 3.86% and revenue of $1.00 billion edging past expectations by 1.42%, even as total … Read more Charles River Laboratories posted a modest but meaningful beat in its third-quarter 2025 results, with non-GAAP EPS of $2.43 clearing the $2.34 consensus estimate by 3.86% and revenue of $1.00 billion edging past expectations by 1.42%, even as total sales slipped 0.5% year-over-year amid persistent softness in its core drug development services business. The primary bright spot was the Research Models and Services segment, which delivered 6.5% organic growth and margin expansion to 25.0%, helping offset continued weakness in the larger Discovery and Safety Assessment segment, where lower volumes compressed margins to 25.4% from 27.4% a year earlier. Adding a degree of relief to the quarter, regulators closed a long-running investigation into the company's non-human primate sourcing practices with no enforcement action recommended. Looking ahead, management narrowed its full-year non-GAAP EPS guidance to $10.10 to $10.30 and tightened the revenue outlook toward the upper end of prior ranges, though CEO James Foster cautioned that a sustained industry recovery remains a gradual and uncertain process.

Key Takeaways

  • • Higher revenue from large research model products drove RMS segment organic growth of 6.5%
  • • Lower sales volume for both discovery and regulated safety assessment services pressured DSA segment
  • • Lower revenue in CDMO and Biologics Testing businesses drove Manufacturing segment decline, partially offset by higher Microbial Solutions revenue
  • • Foreign currency translation provided a 1.3% benefit to reported revenue
  • • Cost savings from restructuring initiatives improved GAAP operating margin to 13.3% from 11.6%
  • • Loss of $0.33 per share from venture capital and strategic investments weighed on GAAP EPS
  • • Lower interest expense and reduced diluted share count from stock repurchases partially offset revenue declines on non-GAAP EPS
  • • Higher tax rate contributed to non-GAAP EPS decline
24/7 Wall St

CRL YoY Financials

Q3 2025 vs Q3 2024, source: SEC Filings

24/7 Wall St

CRL Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 25 Q1 26

“Our solid third-quarter financial results demonstrate that the demand for our extensive portfolio of early-stage research and manufacturing products and services remains stable. We believe that positive signals are beginning to emerge which indicate that the industry may be on a path towards recovery; however, sustained improvement in our business will take time. There is still some uncertainty in the healthcare sector, so we are remaining cautious at this time.”

— James C. Foster, Q3 2025 Earnings Press Release

Back to CRL Stock Page